Brief: Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data Of Its Investigational Subcutaneous (SC) Levothyroxine (Xp-8121) Hosts Conference Call And Webcast

Xeris Biopharma Holdings

20/10/2022 11:17

Oct 20 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 1
CLINICAL DATA
OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE
(XP-8121); HOSTS CONFERENCE CALL AND WEBCAST
    * XERIS BIOPHARMA HOLDINGS INC - SIMULATION MODEL IMPLIES
DOSE
CONVERSION FACTOR OF 4X
    * XERIS BIOPHARMA HOLDINGS INC - XP-8121 IN HEALTHY
VOLUNTEERS WAS
GENERALLY WELL TOLERATED AT ALL DOSES
    * XERIS BIOPHARMA HOLDINGS INC- FDA END-OF-PHASE 1
INTERACTION
EXPECTED BY YEAR-END
    * XERIS - PROOF-OF-CONCEPT SHOWING ONCE WEEKLY SUBCUTANEOUS
INJECTION OF XP-8121 PROVIDES SIMILAR EXPOSURE AT STEADY-STATE
AS DAILY ORAL SYNTHROID

Source text for Eikon:  ID:nBw6zDTD2a 
Further company coverage:  XERS.O 
 ((Reuters.Briefs@thomsonreuters.com;;))